Provided by Tiger Trade Technology Pte. Ltd.

Soleno Therapeutics

41.53
+1.954.93%
Post-market: 41.05-0.4800-1.16%19:57 EST
Volume:1.46M
Turnover:59.51M
Market Cap:2.23B
PE:-23.73
High:41.80
Open:40.32
Low:39.55
Close:39.58
52wk High:90.32
52wk Low:37.95
Shares:53.71M
Float Shares:44.87M
Volume Ratio:0.65
T/O Rate:3.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7500
EPS(LYR):-4.3770
ROE:-20.66%
ROA:-11.75%
PB:4.51
PE(LYR):-9.49

Loading ...

A Look At Soleno Therapeutics (SLNO) Valuation After VYKAT XR Launch And Upcoming 2025 Business Updates

Simply Wall St.
·
Feb 03

Strategic Investment Fuels Confidence in Soleno Therapeutics’ Growth Outlook and Supports Buy Rating

TIPRANKS
·
Jan 29

Guggenheim Keeps Their Buy Rating on Soleno Therapeutics (SLNO)

TIPRANKS
·
Jan 29

Soleno Therapeutics to Participate in Upcoming Conferences

GlobeNewswire
·
Jan 29

Soleno Therapeutics Boosts Executive Pay and Severance Benefits

Reuters
·
Jan 26

Soleno Therapeutics Updates Executive Compensation and Severance Plans

TIPRANKS
·
Jan 24

Soleno Therapeutics (SLNO) Valuation Checked After New Q4 2025 Revenue Guidance

Simply Wall St.
·
Jan 22

Soleno Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 20

Soleno Therapeutics: Strong VYKAT XR Outperformance, Solid Balance Sheet, and Global Growth Optionality Drive Higher Buy-Rated Target

TIPRANKS
·
Jan 20

Stock Track | Soleno Therapeutics Plummets 5.06% Intraday After Baird Cuts Target Price

Stock Track
·
Jan 13

Cantor Fitzgerald Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)

TIPRANKS
·
Jan 13

Soleno Therapeutics (SLNO) Receives a Buy from Wells Fargo

TIPRANKS
·
Jan 13

Soleno Therapeutics: Sustained U.S. Vykat XR Outperformance and European Upside Support Buy Rating and $100 Target

TIPRANKS
·
Jan 13

Soleno Therapeutics price target lowered to $60 from $75 at Wolfe Research

TIPRANKS
·
Jan 13

BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners

Reuters
·
Jan 12

Soleno Therapeutics Reverse Premarket Gains, Last Down 1.7%

THOMSON REUTERS
·
Jan 12

Soleno Therapeutics Preliminary Q4 Net Revenue Beats Analyst Estimates

MT Newswires Live
·
Jan 12

Soleno Therapeutics Projects 2025 Net Revenue of Up to $191 Million

Reuters
·
Jan 12

Soleno Therapeutics Inc Q4 REV View $81.7 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Jan 12

Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results

THOMSON REUTERS
·
Jan 12